OneSource Specialty Pharma Ltd
Incorporated in 2007, OneSource Specialty Pharma Ltd is in the research, development, manufacture and commercialisation of bio
logical drug products in various injectable formats. It also offers end-to-end CDMO
services across all phases of pre-clinical
and clinical development and commercial
supply of biologics[1]
- Market Cap ₹ 22,621 Cr.
- Current Price ₹ 1,977
- High / Low ₹ 2,115 / 1,163
- Stock P/E 171
- Book Value ₹ 517
- Dividend Yield 0.00 %
- ROCE 6.45 %
- ROE 4.19 %
- Face Value ₹ 1.00
Pros
Cons
- Stock is trading at 3.82 times its book value
- Company has low interest coverage ratio.
- Promoter holding has decreased over last quarter: -3.52%
- Company has a low return on equity of -16.7% over last 3 years.
- Debtor days have increased from 92.4 to 124 days.
- Working capital days have increased from -704 days to 80.5 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| 21 | 132 | 39 | 172 | 1,300 | |
| 93 | 228 | 156 | 254 | 930 | |
| Operating Profit | -72 | -96 | -117 | -82 | 369 |
| OPM % | -337% | -72% | -303% | -48% | 28% |
| 1 | 4 | -525 | -143 | -95 | |
| Interest | 16 | 68 | 48 | 89 | 162 |
| Depreciation | 34 | 70 | 109 | 76 | 135 |
| Profit before tax | -121 | -230 | -799 | -390 | -22 |
| Tax % | 0% | 0% | 0% | 0% | -187% |
| -121 | -230 | -799 | -390 | 19 | |
| EPS in Rs | 1.69 | ||||
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 114% |
| TTM: | 656% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 37% |
| TTM: | 149% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | -17% |
| Last Year: | 4% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| Equity Capital | 2 | 4 | 4 | 4 | 11 |
| Reserves | 777 | 1,012 | 783 | 394 | 5,909 |
| 386 | 1,154 | 864 | 571 | 942 | |
| 98 | 275 | 363 | 457 | 528 | |
| Total Liabilities | 1,262 | 2,445 | 2,014 | 1,426 | 7,390 |
| 633 | 1,231 | 1,361 | 863 | 3,346 | |
| CWIP | 382 | 440 | 334 | 188 | 60 |
| Investments | 53 | 52 | 5 | 20 | 2,848 |
| 194 | 722 | 314 | 355 | 1,136 | |
| Total Assets | 1,262 | 2,445 | 2,014 | 1,426 | 7,390 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| -115 | -420 | -165 | -109 | -47 | |
| -210 | -685 | -66 | 506 | -300 | |
| 381 | 1,159 | 118 | -384 | 417 | |
| Net Cash Flow | 56 | 55 | -112 | 13 | 70 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| Debtor Days | 38 | 101 | 35 | 118 | 124 |
| Inventory Days | 87 | 1,720 | 2,354 | 665 | 137 |
| Days Payable | 758 | 408 | 1,606 | 419 | 143 |
| Cash Conversion Cycle | -633 | 1,414 | 784 | 363 | 118 |
| Working Capital Days | -1,116 | 251 | -1,939 | -255 | 81 |
| ROCE % | -10% | -12% | -12% | 6% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
1d - Of Participation of the Company in a Group Investor meeting hosted by Goldman Sachs on June 16, 2025 at Bengaluru, Karnataka, India.
-
Announcement under Regulation 30 (LODR)-Press Release / Media Release
1d - OneSource partners with Xbrane for biosimilars manufacturing, targeting EUR 23bn market, enhancing global supply chain.
-
Announcement under Regulation 30 (LODR)-Press Release / Media Release
2d - OneSource's Bangalore facility cleared USFDA inspection with VAI status, enabling FY26 GLP-1 product launch.
-
General-Updates
2d - Xbrane plans SEK 240m directed share issue to fund FDA process and production, diluting shares by 40.5%.
-
Announcement under Regulation 30 (LODR)-Credit Rating
4 Jun - India Ratings assigns IND A- rating with positive outlook to OneSource Specialty Pharma's INR7,415M bank facilities.
Annual reports
No data available.
Concalls
-
May 2025Transcript PPT
-
Feb 2025Transcript PPT
Business Overview:[1]
OSSPL is a subsidiary of Strides Pharma
Ltd. The company is a Contract Development
and Manufacturing Organisation that caters
to several biopharma and biotech companies.
It covers the entire CDMO value chain, from clinical development to technology transfer
to commercial manufacture and regulatory assistance.